The Form 4 filing was filed on November 12, 2026, the same day as the sale. Form 4 reports an insider's stock transactions to the SEC.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-12 |
| Date of Latest Transaction | 2026-11-12 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 3,180 |
| Price | $191.89 |
| Total Transaction Value | $610,210.20 |
| Insider | |
| Ticker Symbol | BR |
| Company | BROADRIDGE FINANCIAL SOLUTIONS, INC. |
| Insider Name | Markus Maura A. |
| Insider Title | Director |
| Sector - Industry | Technology - Information Technology Services |
| Holdings | |
| Total Shares Owned After Transaction | 33,769.10 |
| Position Size Change | 8.61% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of BR shares, reported under transaction code S. The details also suggest a link to an exercise or conversion. These steps can turn a right to buy shares, or another type of investment, into shares.
What was the average price of the transaction?
The average sale price was $191.89 per share. That price applies to the one reported sale of 3,180 shares.
How did this transaction affect the insider's holdings?
Maura A. Markus sold 3,180 shares and reported 33,769.102 shares owned afterward. The shares sold made up 8.61% of the reported holdings before the sale.
What's the total transaction value?
The total transaction value was $610,210.20 for the single reported sale.
Are there any special circumstances around this transaction?
Yes. The available information includes a Rule 10b5-1 plan reference. These plans set trading instructions in advance. Footnote text is unavailable, so it is unclear whether the reference covers this specific sale.
A matching share count also suggests a link to an exercise or conversion under code M. Details of the related transaction, including its date, type of investment, and account, are unavailable. The match does not confirm that the exact shares received were sold.
For research purposes only; not investment advice.